m+Medelevator.RU
← Поиск публикаций
Vaccines · 2022

Public Health Surveillance for Adverse Events Following COVID-19 Vaccination in Africa.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Anjorin AbdulAzeez Adeyemi, Odetokun Ismail A, Nyandwi Jean Baptiste, Elnadi Hager, Awiagah Kwame Sherrif, Eyedo Joseph, Abioye Ajibola Ibraheem, Gachara George, Maisara Aala MohmedOsman, Razouqi Youssef, Yusuf Mohamud Mohamed Farah, Mhgoob Zuhal Ebrahim, Ajayi Tunde, Ntirenganya Lazare, Saibu Morounke, Salako Babatunde Lawal, Elelu Nusirat, Wright Kikelomo Ololade, Fasina Folorunso O, Mosbah Rasha

Аннотация

Local, national, and international health agencies have advocated multi-pronged public health strategies to limit infections and prevent deaths. The availability of safe and effective vaccines is critical in the control of a pandemic. Several adverse events have been reported globally following reception of different vaccines, with limited or no data from Africa. This cross-sectional epidemiological study investigated adverse events following COVID-19 vaccination in Africans from April-June, 2021 using a structured online questionnaire. Out of 1200 participants recruited, a total of 80.8% (n = 969) respondents from 35 countries, including 22 African countries and 13 countries where Africans live in the diaspora, reported adverse events. Over half of the vaccinees were male (53.0%) and frontline healthcare workers (55.7%), respectively. A total of 15.6% (n = 151) reported previous exposure to SARS-CoV-2, while about one-fourth, 24.8% (n = 240), reported different underlying health conditions prior to vaccination. Fatal cases were 5.1% (n = 49), while other significant heterogenous events were reported in three categories: very common, common, and uncommon, with the latter including enlarged lymph nodes 2.4% (n = 23), menstrual disorder 0.5% (n = 5), and increased libido 0.2% (n = 2). The study provided useful data for concerned authorities and institutions to prepare plans that will address issues related to COVID-19 vaccines.